News brief­ing: Mar­ius sub­mits NDA for oral hy­pog­o­nadism ther­a­py; Cell­tri­on's bil­lion­aire founder steps down

US reg­u­la­tors will soon be look­ing at a new testos­terone re­place­ment ther­a­py, if Mar­ius Phar­ma­ceu­ti­cals has its way.

The Raleigh, North Car­oli­na-based biotech

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER